ondansetron has been researched along with Lupus Erythematosus, Cutaneous, Subacute in 1 studies
Ondansetron: A competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Yung, RL | 1 |
| Richardson, BC | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| [NCT00004643] | Phase 2 | 10 participants | Interventional | 1995-02-28 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 other study available for ondansetron and Lupus Erythematosus, Cutaneous, Subacute
| Article | Year |
|---|---|
Cytarabine therapy for refractory cutaneous lupus.
Topics: Adult; Antimetabolites, Antineoplastic; Cytarabine; Drug Therapy, Combination; Female; Humans; Lupus | 1995 |